Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. Its products include genetic engineering vaccines and multivalent vaccines. The company also provides technical services. Pulike Biological Engineering was founded in 1995 and is headquartered in Luoyang, China.

Qinghai Upper Yellow River Hydropower Development Co., Ltd., established on 2008-05-28, Business scope includes licensed projects:Power generation business,Transmission business,for(match)Electric business;Hazardous Chemicals Management(Only licensed branches operate)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Electronic special material manufacturing;Sales of electronic special materials;Photovoltaic equipment and components sales;Manufacturing of photovoltaic equipment and components;Manufacture of non-metallic mineral products;Sales of non-metallic minerals and products;Sales of high-performance non-ferrous metals and alloy materials;Manufacturing of non-ferrous metal alloys;Non-ferrous metal rolling processing;Manufacture of graphite and carbon products;Sales of graphite and carbon products;Import and export;Import and export agency;Heat production and supply;Sales of renewable resources;Lime and Gypsum Manufacturing;Lime and Gypsum Sales;business training(Does not include education and training,Vocational skills training and other licensed training);Conference and Exhibition Services;Machinery and Equipment Leasing;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Manufacturing of power transmission and distribution and control equipment;Sales of new energy original moving equipment;Solar Power Technology Services;Intelligent power transmission and distribution and control equipment sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Huanghe Xinye Co., Ltd., established on 2010-10-29, Business scope includes licensed projects:electric wire,cable manufacturing;Power facility installation,undertook,Take the test;Various construction activities;road freight transport(Does not contain dangerous goods);Inspection and testing service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Common non-ferrous metal smelting;Metal material manufacturing;Metal Material Sales;Non-ferrous metal rolling processing;Manufacture of graphite and carbon products;Sales of graphite and carbon products;R&D of metal products;Non-residential real estate leases;Synthetic Materials Sales;Petroleum product sales(Free of Hazardous Chemicals);General machinery and equipment installation services;General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval);Loading and unloading;Photovoltaic equipment and components sales;Mechanical and electrical equipment manufacturing;Sales of electrical machinery and equipment;Metalworking machinery manufacturing;electric wire,cable management;Solar Power Technology Services;Mechanical equipment research and development;New material technology research and development;Power Generation Technical Services;sales agent(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

State Power Investment Group Upper Yellow River Hydropower Development Co., Ltd., established on 1999-10-19, Business scope includes development and construction of power stations,Power station production,operate;Production of silicon products and solar power generation equipment,Sales;Aluminum ingot,Aluminum liquid,Sales of aluminum alloy and aluminum profiles;Sales of carbon products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

BioLife Solutions is located in Bothell, Washington, on a high-tech campus that has its roots as a dairy farm. They design, manufacture, and market proprietary and generic cGMP biopreservation media products for cells, tissues, and organs. They also perform contract research and offer consulting to optimize customer specific biopreservation protocols and processes. And for their direct, distributor, and contract customers, They perform custom formulation, fill, and finish services.

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Donaldson Co., Inc. engages in the manufacture of filtration systems and replacement parts. It operates through the following segments: Engine Products and Industrial Products. The Engine Products segment includes replacement filters for both air and liquid filtration applications, air filtration systems, liquid filtration systems for fuel, lube and hydraulic applications, and exhaust and emissions systems. The Industrial Products segment consist of dust, fume and mist collectors, compressed air purification systems, air filtration systems for gas turbines, polytetrafluoroethylene membrane-based products, and specialized air and gas filtration systems for applications as well as hard disk drives, and semi-conductor manufacturing. The company was founded by Frank Donaldson in 1915 and is headquartered in Minneapolis, MN.

AVIC (Ningxia) Biological Co., Ltd., established on 1995-12-19, Business scope includes bone marrow,cord blood,Development of peripheral blood nucleated cell processing kit and improved nucleated cell processing kit,production and sales;Research and development of cytokine cosmetics,Sales;II:6841Medical testing and basic equipment sales;III:6866Sales of medical polymer materials and products;cord blood cells(non-hematopoietic stem cells),adult peripheral blood immune cells,Adult fat stem cell storage and collection;placenta,Umbilical cord mesenchymal stem cell storage and collection preparation and related business;cord blood,Peripheral blood storage and collection;Technology Import and Export,Import and export(Except where prohibited by laws and regulations);Medical intermediary service;Technical Services;Office Supplies Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

CellRev is a biotechnology company focused on process intensification within cell manufacturing applications. The company’s proprietary technology facilitates the transition from batch to continuous processing of adherent cells. It’s a disruptive new biomanufacturing approach that increases yield while decreasing operating costs and capital expenditure. A proprietary cell detachment process is complemented by a specially designed bioprocess; together, they pose an altogether unique cell manufacturing solution.

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. The platforms can be used to enhance existing stem-cell forward programming methods, or bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. Behind its lead, Stemline is developing a broad portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. In addition, Stemline has built a robust discovery platform called “StemScreen®” which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. Stemline also possesses a comprehensive intellectual property portfolio that includes the earliest filings in the cancer stem cell field covering cancer stem cell-directed therapeutics, diagnostics, and drug screening.

Shenzhen Clou Electronics Co., Ltd. (科陆电子) is the supplier of intelligent electricity core equipment for the State Grid Corporation of China. It is a national high-tech enterprise, with the largest market share in the standard electrical instrumentation market. Clou Electronics successfully developed a series of national initiative products for the fields of advanced electric measurement, electric energy measuring, and clients' electricity load management in 1997, 2001, and 2004, respectively.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

Zhaofenghua Biotechnology (Fuzhou) Co., Ltd., established on 2003-05-26, Business scope includes technical development of biological products,Technical Services,Technology Transfer and Technology Consulting;Medical Research and Experimental Development;Agricultural Science Research and Experimental Development;Biopharmaceutical Manufacturing;Genetically engineered drugs and vaccine manufacturing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Chengdu Shiji Bio-Pharmaceutical Co., Ltd., established on 2003-04-15, Business scope includes licensed projects:Veterinary drug production;Veterinary drug business;Breeding livestock and poultry management(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Agricultural Science Research and Experimental Development;Bio-feed R&D;Pet Food and Supplies Wholesale;Pet food and supplies retail;Experimental analysis instrument sales;Specialty Chemicals Sales(Free of Hazardous Chemicals);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;internet sales(Except for products that require a license for sale);Import and export;Technology Import and Export;Import and export agency;farming,Forest,animal husbandry,vice,Sales of fishery specialized machinery(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Guangzhou Yuyue Biotechnology Co., Ltd., established on 2014-07-29, Business scope includes natural science research and experimental development;Biotechnology Extension Services;Biotechnology Development Services;Biotechnology Consulting,communication service;Biotechnology Transfer Services;

Beijing Selfusen Biotechnology Co., Ltd., established on 2011-12-05, Business scope includes technology development,Technology Promotion,technology transfer,technical consulting,Technical Services,Technical Training;Sales of chemical products(Does not contain dangerous chemicals and a class of precursor chemicals),medical instruments(limitIkind),Instrumentation.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Nanjing Tianbang Bio Technology Co., Ltd., part of Beijing Dabeinong Technology Group Co., Ltd., is a Chinese company located in Nanjing. The firm engages in researching and developing animal bio products. On March 12, 2014 Beijing Dabeinong Technology Group Co., Ltd. acquired Nanjing Tianbang Bio Technology Co., Ltd. for $1.94 million.